interest and miscellaneous income was $ 4,026,000 for the year ended december 31 , 2015 as compared to $ 45,000 for the same period of 2014 , an increase of $ 3,981,000. miscellaneous income is higher in 2015 than for the same period in 2014 due to change in fair value of our contingent consideration liability ( $ 3,898,000 ) related to the acquisition of abeona ohio and write-offs of certain accounts payables ( $ 38,000 ) and interest income ( $ 45,000 ) . interest and other expense was $ 6,000 for the year ended december 31 , 2015 as compared to $ 582,000 in the same period of 2014 , a decrease of $ 576,000. the interest in 2014 represents interest accrued on unpaid dividends . all dividends and accrued interest on dividends due were paid in december 2014. there are no more dividends accruing . we recorded a loss for the derivative liability related to preferred stock of $ 23,110,000 for the year ended december 31 , 2014. the preferred stock related to the dividends was converted into common stock in december 2014. preferred stock dividends of $ 2,875,000 were accrued for the year ended december 31 , 2014. the preferred stock related to the dividends was converted into common stock in december 2014. net loss allocable to common stockholders for the year ended december 31 , 2015 was $ 14,526,000 , or a $ 0.53 basic and diluted loss per common share as compared to a net loss of $ 29,653,000 , or a $ 15.26 basic and diluted loss per common share , for the same period in 2014 , a decreased loss of $ 15,127,000. story_separator_special_tag trials ; · the costs involved in filing , prosecuting and enforcing patent claims ; · the costs involved in conducting clinical trials ; · competing technological developments ; · the cost of manufacturing and scale-up ; · the ability to establish and maintain effective commercialization arrangements and activities ; and · successful regulatory filings . we have devoted substantially all of our efforts and resources to research and development conducted on our own behalf . the following table summarizes research and development spending by project category , which spending includes , but is not limited to , payroll and personnel expense , lab supplies , preclinical expense , development cost , clinical trial expense , outside manufacturing expense and consulting expense : replace_table_token_2_th ( 1 ) cumulative spending from inception of the company or project through december 31 , 2015 . ( 2 ) includes other projects which the company is no longer focused . 32 due to uncertainties and certain of the risk factors described above , including those relating to our ability to successfully commercialize our drug candidates , our ability to obtain necessary additional capital to fund operations in the future , our ability to successfully manufacture our products and our product candidates in clinical quantities or for commercial purposes , government regulation to which we are subject , the uncertainty associated with preclinical and clinical testing , intense competition that we face , market acceptance of our products and protection of our intellectual property , it is not possible to reliably predict future spending or time to completion by project or product category or the period in which material net cash inflows from significant projects are expected to commence . if we are unable to timely complete a particular project , our research and development efforts could be delayed or reduced , our business could suffer depending on the significance of the project and we might need to raise additional capital to fund operations , as discussed in the risk factors above , including without limitation those relating to the uncertainty of the success of our research and development activities and our ability to obtain necessary additional capital to fund operations in the future . as discussed in such risk factors , delays in our research and development efforts and any inability to raise additional funds could cause us to eliminate one or more of our research and development programs . we plan to continue our policy of investing any available funds in certificates of deposit , money market funds , government securities and investment-grade interest-bearing securities . we do not invest in derivative financial instruments . we do not believe inflation or changing prices have had a material impact on our revenue or operating costs in the past three years . climate change we do not believe there is anything unique to our business which would result in climate change regulations having a disproportional effect on us as compared to u.s. industry overall . critical accounting policies and estimates the preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the u.s. requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities , disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period . in applying our accounting principles , we must often make individual estimates and assumptions regarding expected outcomes or uncertainties . as you might expect , the actual results or outcomes are often different than the estimated or assumed amounts . these differences are usually minor and are included in our consolidated financial statements as soon as they are known . our estimates , judgments and assumptions are continually evaluated based on available information and experience . because of the use of estimates inherent in the financial reporting process , actual results could differ from those estimates . receivables receivables are reported in the balance sheets at the outstanding amount net of an allowance for doubtful accounts . we continually evaluate the creditworthiness of our customers and their financial condition and generally do not require collateral . story_separator_special_tag the allowance for doubtful accounts is based upon reviews of specific customer balances , historic losses , and general economic conditions . as of december 31 , 2015 and 2014 , no allowance was recorded as all accounts were considered collectible . 33 licensed technology we maintain licensed technology on our consolidated balance sheet until either the licensed technology agreement underlying it is completed or the asset becomes impaired . when we determine that an asset has become impaired or we abandon a project , we write down the carrying value of the related intangible asset to its fair value and take an impairment charge in the period in which the impairment occurs . generally licensed technology is amortized over the life of the patent or the agreement . we test our intangible assets for impairment on an annual basis , or more frequently if indicators are present or changes in circumstance suggest that impairment may exist . events that could result in an impairment , or trigger an interim impairment assessment , include the receipt of additional clinical or nonclinical data regarding our drug candidate or a potentially competitive drug candidate , changes in the clinical development program for a drug candidate or new information regarding potential sales for the drug . in connection with each annual impairment assessment and any interim impairment assessment , we compare the fair value of the asset as of the date of the assessment with the carrying value of the asset on our consolidated balance sheet . in 2015 , we did not impair any licensed technology . gene therapy license agreements on may 15 , 2015 , we acquired abeona therapeutics llc which had a an exclusive license through nationwide children 's hospital to the ab-101 and ab-102 patent portfolios for developing treatments for patients with sanfilippo syndrome type a and type b. this portfolio comprises 1 patent family : “ products and methods for delivery of polynuleotides by adeno-associated virus for lysosomal storage disorders ” . additionally , abeona has secured fda orphan drug designation for both sanfilippo a and b , which will provide 7 years of post-launch market exclusivity for both abx-a and abx-b in the u.s. abeona will be seeking orphan drug status within the ema , which will grant 10 years of post-market exclusivity in the european union . the license is amortized over the life of the license of 20 years . on june 5 , 2015 , we entered into an exclusive , worldwide , licensing agreement with the unemed corporation , the technology transfer and commercialization office for the university of nebraska medical center ( unmc ) in omaha , nebraska , for an aav gene therapy for the treatment of juvenile batten disease . we licensed the rights to two patents ( 62/092,501 and 62/146,793 ) . under the terms of the licensing agreement , we paid a license fee of $ 75,000 and will pay milestone payments on certain milestone events . commencing with the first commercial sale of licensed products a royalty will be paid . terms of the agreement require we execute a sponsored research agreement with unmc focused on additional efficacy studies within 12 months . on october 14 , 2015 we entered into a sponsored research agreement with unmc to support ongoing aav9/cln3 projects in the amount of $ 215,000. on june 5 , 2015 , we entered into an exclusive , worldwide , licensing agreement with the university of minnesota for an aav gene therapy for the treatment of patients with fanconi anemia ( fa ) disorder and other rare blood diseases . we licensed one patent ( 62/000,590 ) , method for editing a genetic sequence . under terms of the licensing agreement , we paid a license fee of $ 80,000 , will pay an additional license fee of $ 50,000 , will pay annual maintenance fees and a royalty fee with the first commercial sale of licensed products . on september 17 , 2015 , we entered into a nonexclusive license agreement with stanford university for an aav delivery vector for the treatment of fa and rare blood disease platform . this license augments the university of minnesota agreement . we licensed two patents ( 13/594,773 and epo 12756603.2 ) . under terms of the licensing agreement , we paid a license fee of $ 25,000 , will pay annual maintenance fees and a royalty fee with the first commercial sale of licensed products . plasma-based therapeutics license agreements on september 22 , 2014 , we entered into an exclusive , worldwide licensing agreement with licensor to obtain rights to utilize and to sub-license to other pharmaceuticals firms , its patented methods for the extraction of therapeutic biologics from human plasma . under the terms of the licensing agreement , as amended on january 23 , 2015 , we paid a license fee of $ 1 million in cash , will pay $ 4,000,000 in cash or 1,096,151 shares of our common stock in 2017 , a regulatory approval milestone payment of 513,375 shares of our common stock upon the first fda regulatory approval of a drug derived from the licensor 's proprietary sdf process , and a tiered royalty on annual net sales of plasma fractions produced with licensor 's proprietary sdf process . the license is amortized over the life of the patent of 11 years . goodwill as of december 31 , 2015 , goodwill of $ 32.5 million was recorded on the company 's balance sheet . the implied fair value of goodwill represented the excess of the abeona ohio 's value over and above the fair value of its tangible assets and identifiable intangible assets . in accordance with accounting standards codification ( “ asc ” ) no . 350 — intangibles — goodwill and other , goodwill is not amortized , but is rather tested annually for impairment and whenever changes in circumstances occur that would indicate impairment

liquidity and capital resources we have historically funded our operations primarily through public and private sales of common stock , preferred stock , convertible notes and through licensing agreements . our principal source of liquidity is cash and cash equivalents . licensing payments and royalty revenues provided limited funding for operations during the period ended december 31 , 2015. as of december 31 , 2015 , our cash and cash equivalents were $ 40,138,000. as of december 31 , 2015 , our working capital was $ 39,091,000. our working capital at december 31 , 2015 represented an increase of $ 30,434,000 as compared to our working capital as of december 31 , 2014 of $ 8,657,000. the net increase in the working capital at december 31 , 2015 reflects financings , warrant exercises and the acquisition of abeona therapeutics llc ( abeona ohio ) less twelve months of net operating costs and changes in current assets and liabilities . on july 31 , 2015 we closed an upsized $ 15.5 million direct placement of registered common stock with institutional investors , including soros fund management and perceptive life science fund , and two members of our board of directors . the financing was comprised of 2.83 million shares of our common stock at a price of $ 5.50 per share . on may 11 , 2015 , we closed a $ 10 million private placement of common stock consisting of 1,250,000 shares of our common stock , at a price of $ 8.00 per share and warrants to purchase 625,000 shares of common stock . the warrants have an exercise price of $ 8.00 per share and are exercisable for 30 months from the closing date .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources we have historically funded our operations primarily through public and private sales of common stock , preferred stock , convertible notes and through licensing agreements . our principal source of liquidity is cash and cash equivalents . licensing payments and royalty revenues provided limited funding for operations during the period ended december 31 , 2015. as of december 31 , 2015 , our cash and cash equivalents were $ 40,138,000. as of december 31 , 2015 , our working capital was $ 39,091,000. our working capital at december 31 , 2015 represented an increase of $ 30,434,000 as compared to our working capital as of december 31 , 2014 of $ 8,657,000. the net increase in the working capital at december 31 , 2015 reflects financings , warrant exercises and the acquisition of abeona therapeutics llc ( abeona ohio ) less twelve months of net operating costs and changes in current assets and liabilities . on july 31 , 2015 we closed an upsized $ 15.5 million direct placement of registered common stock with institutional investors , including soros fund management and perceptive life science fund , and two members of our board of directors . the financing was comprised of 2.83 million shares of our common stock at a price of $ 5.50 per share . on may 11 , 2015 , we closed a $ 10 million private placement of common stock consisting of 1,250,000 shares of our common stock , at a price of $ 8.00 per share and warrants to purchase 625,000 shares of common stock . the warrants have an exercise price of $ 8.00 per share and are exercisable for 30 months from the closing date .
```    
 Suspicious Activity Report : interest and miscellaneous income was $ 4,026,000 for the year ended december 31 , 2015 as compared to $ 45,000 for the same period of 2014 , an increase of $ 3,981,000. miscellaneous income is higher in 2015 than for the same period in 2014 due to change in fair value of our contingent consideration liability ( $ 3,898,000 ) related to the acquisition of abeona ohio and write-offs of certain accounts payables ( $ 38,000 ) and interest income ( $ 45,000 ) . interest and other expense was $ 6,000 for the year ended december 31 , 2015 as compared to $ 582,000 in the same period of 2014 , a decrease of $ 576,000. the interest in 2014 represents interest accrued on unpaid dividends . all dividends and accrued interest on dividends due were paid in december 2014. there are no more dividends accruing . we recorded a loss for the derivative liability related to preferred stock of $ 23,110,000 for the year ended december 31 , 2014. the preferred stock related to the dividends was converted into common stock in december 2014. preferred stock dividends of $ 2,875,000 were accrued for the year ended december 31 , 2014. the preferred stock related to the dividends was converted into common stock in december 2014. net loss allocable to common stockholders for the year ended december 31 , 2015 was $ 14,526,000 , or a $ 0.53 basic and diluted loss per common share as compared to a net loss of $ 29,653,000 , or a $ 15.26 basic and diluted loss per common share , for the same period in 2014 , a decreased loss of $ 15,127,000. story_separator_special_tag trials ; · the costs involved in filing , prosecuting and enforcing patent claims ; · the costs involved in conducting clinical trials ; · competing technological developments ; · the cost of manufacturing and scale-up ; · the ability to establish and maintain effective commercialization arrangements and activities ; and · successful regulatory filings . we have devoted substantially all of our efforts and resources to research and development conducted on our own behalf . the following table summarizes research and development spending by project category , which spending includes , but is not limited to , payroll and personnel expense , lab supplies , preclinical expense , development cost , clinical trial expense , outside manufacturing expense and consulting expense : replace_table_token_2_th ( 1 ) cumulative spending from inception of the company or project through december 31 , 2015 . ( 2 ) includes other projects which the company is no longer focused . 32 due to uncertainties and certain of the risk factors described above , including those relating to our ability to successfully commercialize our drug candidates , our ability to obtain necessary additional capital to fund operations in the future , our ability to successfully manufacture our products and our product candidates in clinical quantities or for commercial purposes , government regulation to which we are subject , the uncertainty associated with preclinical and clinical testing , intense competition that we face , market acceptance of our products and protection of our intellectual property , it is not possible to reliably predict future spending or time to completion by project or product category or the period in which material net cash inflows from significant projects are expected to commence . if we are unable to timely complete a particular project , our research and development efforts could be delayed or reduced , our business could suffer depending on the significance of the project and we might need to raise additional capital to fund operations , as discussed in the risk factors above , including without limitation those relating to the uncertainty of the success of our research and development activities and our ability to obtain necessary additional capital to fund operations in the future . as discussed in such risk factors , delays in our research and development efforts and any inability to raise additional funds could cause us to eliminate one or more of our research and development programs . we plan to continue our policy of investing any available funds in certificates of deposit , money market funds , government securities and investment-grade interest-bearing securities . we do not invest in derivative financial instruments . we do not believe inflation or changing prices have had a material impact on our revenue or operating costs in the past three years . climate change we do not believe there is anything unique to our business which would result in climate change regulations having a disproportional effect on us as compared to u.s. industry overall . critical accounting policies and estimates the preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the u.s. requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities , disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period . in applying our accounting principles , we must often make individual estimates and assumptions regarding expected outcomes or uncertainties . as you might expect , the actual results or outcomes are often different than the estimated or assumed amounts . these differences are usually minor and are included in our consolidated financial statements as soon as they are known . our estimates , judgments and assumptions are continually evaluated based on available information and experience . because of the use of estimates inherent in the financial reporting process , actual results could differ from those estimates . receivables receivables are reported in the balance sheets at the outstanding amount net of an allowance for doubtful accounts . we continually evaluate the creditworthiness of our customers and their financial condition and generally do not require collateral . story_separator_special_tag the allowance for doubtful accounts is based upon reviews of specific customer balances , historic losses , and general economic conditions . as of december 31 , 2015 and 2014 , no allowance was recorded as all accounts were considered collectible . 33 licensed technology we maintain licensed technology on our consolidated balance sheet until either the licensed technology agreement underlying it is completed or the asset becomes impaired . when we determine that an asset has become impaired or we abandon a project , we write down the carrying value of the related intangible asset to its fair value and take an impairment charge in the period in which the impairment occurs . generally licensed technology is amortized over the life of the patent or the agreement . we test our intangible assets for impairment on an annual basis , or more frequently if indicators are present or changes in circumstance suggest that impairment may exist . events that could result in an impairment , or trigger an interim impairment assessment , include the receipt of additional clinical or nonclinical data regarding our drug candidate or a potentially competitive drug candidate , changes in the clinical development program for a drug candidate or new information regarding potential sales for the drug . in connection with each annual impairment assessment and any interim impairment assessment , we compare the fair value of the asset as of the date of the assessment with the carrying value of the asset on our consolidated balance sheet . in 2015 , we did not impair any licensed technology . gene therapy license agreements on may 15 , 2015 , we acquired abeona therapeutics llc which had a an exclusive license through nationwide children 's hospital to the ab-101 and ab-102 patent portfolios for developing treatments for patients with sanfilippo syndrome type a and type b. this portfolio comprises 1 patent family : “ products and methods for delivery of polynuleotides by adeno-associated virus for lysosomal storage disorders ” . additionally , abeona has secured fda orphan drug designation for both sanfilippo a and b , which will provide 7 years of post-launch market exclusivity for both abx-a and abx-b in the u.s. abeona will be seeking orphan drug status within the ema , which will grant 10 years of post-market exclusivity in the european union . the license is amortized over the life of the license of 20 years . on june 5 , 2015 , we entered into an exclusive , worldwide , licensing agreement with the unemed corporation , the technology transfer and commercialization office for the university of nebraska medical center ( unmc ) in omaha , nebraska , for an aav gene therapy for the treatment of juvenile batten disease . we licensed the rights to two patents ( 62/092,501 and 62/146,793 ) . under the terms of the licensing agreement , we paid a license fee of $ 75,000 and will pay milestone payments on certain milestone events . commencing with the first commercial sale of licensed products a royalty will be paid . terms of the agreement require we execute a sponsored research agreement with unmc focused on additional efficacy studies within 12 months . on october 14 , 2015 we entered into a sponsored research agreement with unmc to support ongoing aav9/cln3 projects in the amount of $ 215,000. on june 5 , 2015 , we entered into an exclusive , worldwide , licensing agreement with the university of minnesota for an aav gene therapy for the treatment of patients with fanconi anemia ( fa ) disorder and other rare blood diseases . we licensed one patent ( 62/000,590 ) , method for editing a genetic sequence . under terms of the licensing agreement , we paid a license fee of $ 80,000 , will pay an additional license fee of $ 50,000 , will pay annual maintenance fees and a royalty fee with the first commercial sale of licensed products . on september 17 , 2015 , we entered into a nonexclusive license agreement with stanford university for an aav delivery vector for the treatment of fa and rare blood disease platform . this license augments the university of minnesota agreement . we licensed two patents ( 13/594,773 and epo 12756603.2 ) . under terms of the licensing agreement , we paid a license fee of $ 25,000 , will pay annual maintenance fees and a royalty fee with the first commercial sale of licensed products . plasma-based therapeutics license agreements on september 22 , 2014 , we entered into an exclusive , worldwide licensing agreement with licensor to obtain rights to utilize and to sub-license to other pharmaceuticals firms , its patented methods for the extraction of therapeutic biologics from human plasma . under the terms of the licensing agreement , as amended on january 23 , 2015 , we paid a license fee of $ 1 million in cash , will pay $ 4,000,000 in cash or 1,096,151 shares of our common stock in 2017 , a regulatory approval milestone payment of 513,375 shares of our common stock upon the first fda regulatory approval of a drug derived from the licensor 's proprietary sdf process , and a tiered royalty on annual net sales of plasma fractions produced with licensor 's proprietary sdf process . the license is amortized over the life of the patent of 11 years . goodwill as of december 31 , 2015 , goodwill of $ 32.5 million was recorded on the company 's balance sheet . the implied fair value of goodwill represented the excess of the abeona ohio 's value over and above the fair value of its tangible assets and identifiable intangible assets . in accordance with accounting standards codification ( “ asc ” ) no . 350 — intangibles — goodwill and other , goodwill is not amortized , but is rather tested annually for impairment and whenever changes in circumstances occur that would indicate impairment

